GPRC5A/CXCL8/NLRP3-mediated neutrophil extracellular traps drive gemcitabine-nab-paclitaxel resistance in pancreatic adenocarcinoma
Objective: Gemcitabine combined with nab-paclitaxel therapy (GnP) represents first-line chemotherapy for advanced pancreatic ductal adenocarcinoma (PDAC). However, the efficacy of GnP is diminished due to chemotherapeutic resistance induced by the tumor microenvironment (TME), the underlying mechani...
Saved in:
| Main Authors: | Tianyi Zhu, Qianwen Yang, Xiaozhe Qian, Xiuqi Wu, Jianchen Fang, Yuli Lin, Yukuan Feng, Jian Gao, Qing Xia |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2025-07-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | https://www.cancerbiomed.org/content/22/7/832 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
GPRC6A as a novel kokumi receptor responsible for enhanced taste preferences by ornithine
by: Takashi Yamamoto, et al.
Published: (2025-05-01) -
Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
by: Wenjie Liu, et al.
Published: (2025-04-01) -
METHYLATION AND EXPRESSION VALIDATION RESULTS OF GPRC5C GENE OBTAINED FROM EPIGENOMICS AND TRANSCRIPTOMICS DATA IN ORAL CAVITY TUMORS
by: Gizem Esentürk, et al.
Published: (2022-08-01) -
Adaptive RSK‐EphA2‐GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer
by: Lidia Moyano‐Galceran, et al.
Published: (2020-03-01) -
Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma
by: Sijia Yan, et al.
Published: (2025-03-01)